drugset / Trial / NCT02099825

Medication Enhanced Rapid Therapy

NCT02099825

Phase 1 Terminated 15 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine whether taking a one-time dose of a combination of putatively learning-enhancing medications can improve treatment response to a brief learning-based psychotherapy for public speaking anxiety. The two medications are (1) d-cycloserine (DCS), a medication that is an agonist (facilitator) of the NMDA glutamatergic receptor and has been shown in previous studies to facilitate some kinds of learning and memory; and (2) mifepristone, a medication that blocks cortisol, and in preclinical (animal) studies has been shown to reverse certain kinds of stress-related learning impairment or negative learning. Specifically, the investigators goal is to determine if DCS and mifepristone taken together augment the learning that occurs during a brief psychotherapy session---a public speaking exposure exercise. Evidence for this learning effect would be a finding that participants have reduced anxiety at subsequent public speaking exposures.

Timeline

Start
2014-01-13
Primary completion
2022-10
Completion
2022-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 250 mg
Subject Mifepristone Small molecule 1200 mg

Indications